On November 3, 2016 ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, reported that four abstracts highlighting data from the Company’s adoptive cell-based therapeutic programs have been accepted for presentation at the 58th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, Ziopharm, NOV 3, 2016, View Source [SID1234516531])The meeting will be held December 3-6, 2016 in San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The research, conducted at The University of Texas MD Anderson Cancer Center and Intrexon Corporation (NYSE:XON) demonstrates, among other results, that T cells can be quickly produced with the Sleeping Beauty system and that this non-viral approach to gene therapy can be harnessed to generate chimeric antigen receptor (CAR) and T-cell receptor (TCR) expressing effector cells.
"This suite of nonclinical data underscores the technology underlying our adoptive cell-based programs, including the potential for the Sleeping Beauty platform to improve the manufacture of genetically modified T cells and our ability to redirect T-cell specificity to blood cancers and solid tumors using CARs and TCRs," said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. "This research advances our plans to rapidly and cost-effectively deliver engineered T cells, and we look forward to seeing it translate into clinical programs."
Details for ASH (Free ASH Whitepaper) presentations are as follows:
Title: Very Rapid Production of CAR+T Cells upon Non-viral Gene Transfer using the Sleeping Beauty System
Session Title: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation
Date and Time: Sunday, December 4, 2016, 6:00 — 8:00 p.m. PT
Publication ID: 2807
Location: San Diego Convention Center, Hall GH
Title: Personalization of T-cell Therapy using a High-throughput Platform to Identify Tumor-specific T-cell Receptors
Session Title: 703. Adoptive Immunotherapy: Poster II
Date and Time: Sunday, December 4, 2016, 6:00 — 8:00 p.m. PT
Publication ID: 3359
Location: San Diego Convention Center, Hall GH
Title: Combination Immunotherapy with NY-ESO-1 Specific CAR+T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect
Session Title: 703. Adoptive Immunotherapy: Poster II
Date and Time: Sunday, December 4, 2016, 6:00 — 8:00 p.m. PT
Publication ID: 3366
Location: San Diego Convention Center, Hall GH
Title: Chimeric Antigen Receptor-Modified T Cells for the Treatment of Acute Myeloid Leukemia Expressing CD33
Session Title: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Date and Time: Monday, December 5, 2016, 6:00 — 8:00 p.m. PT
Publication ID: 4058
Location: San Diego Convention Center, Hall GH